Barker, C

Barrett, A

Fahrleitner-Pammer, A

Jakob, F

Karras, D

Langdahl, B

Lems, W F

Ljunggren, O

Marin, F

Oertel, H

Rajzbaum, G

Walsh, J B

English

PubMed

Jakob, F.

Oertel, H.

Langdahl, B.

Barrett, A.

Karras, D.

Walsh, J.B.

Fahrleitner-Pammer, A.

Razjbaum, G.

Barker, C.

Lems, W.F.

Marin, F.

NARCIS 

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36 month results from the European Forsteo Observational Study

(doi:10.1185/03007995.2010.488516) Received 23

and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 166 www.eje-online.orgSantora AC, Liberman UA & Alendronate Phase III Osteoporosis Treatment Study Group . Ten years’ experience with alendronate for osteoporosis in postmenopausal women.

Back pain in osteoporotic vertebral fractures.

Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based ﬁnite element analysis of the vertebral body. Bone

Bouter LM & de Vet HC. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine

Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Current Medical Research and Opinion

Clinical consequences of vertebral fractures.

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.

Effects of longterm risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis.

Evidencebased guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporosis International

Fahrleitner-Pammer A & Pavo I. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.

for the EUROFORS Investigators . Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.

Fracture incidence and changes in qualityof life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporosis International

Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).

From randomized controlled trials to observational studies.

Gluer CC & for the EUROFORS High Resolution Computed Tomography Substudy Group . Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study.

Group. Earlychanges in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.

Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.

Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.

Improvements in vertebral body strength under teriparatide treatment assessed in vivo by ﬁnite element analysis: results from the EUROFORS study.

Kutahov A & Marin F. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide:

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.

Longitudinal data analysis using generalized linear models. Biometrika

Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone

Measuring self reported population health: an international perspective based on EQ-5D.

month data from the European Forsteo Observational Study (EFOS).

months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study.

pain during different sequential treatment regimens of teriparatide: results from EUROFORS.

Pharmacokinetics of alendronate. Clinical Pharmacokinetics

Quality of life in patients with osteoporosis.

Quantitative computed tomographic assessment of the effects of

Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.

Rizzoli R & on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) . European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Study subjects and ordinary patients.

Summary of Product Characteristics. Available from: http://www.ema.europa.eu/ema/index.jsp?curlZ pages/medicines/human/medicines/000425/human_-med_000798.jsp&murlZmenus/medicines/medicines.jsp&jsenabledZtrue.

Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice. Calciﬁed Tissue International

The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.

The EuroQol Group. EuroQoL – a new facility for the measurement of health-related quality of life. Health Policy

WD & for the EUROFORS Investigators . Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3232638

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study

Abstract

Similar works

Full text

Available Versions

NARCIS